Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 22.02
(4.61%)
CNY 22.02
(4.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 768.68 Million CNY | -66.56% |
| 2022 | 2.45 Billion CNY | 61.98% |
| 2021 | 1.51 Billion CNY | 6.08% |
| 2020 | 1.43 Billion CNY | 532.28% |
| 2019 | 226.29 Million CNY | 60.54% |
| 2018 | 140.96 Million CNY | 56.63% |
| 2017 | 89.99 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 212.24 Million CNY | -22.83% |
| 2024 Q2 | 216.89 Million CNY | 2.19% |
| 2024 Q3 | 235.55 Million CNY | 8.6% |
| 2023 Q1 | 207.51 Million CNY | -73.38% |
| 2023 FY | 822.17 Million CNY | -66.56% |
| 2023 Q4 | 275.02 Million CNY | 34.94% |
| 2023 Q3 | 203.81 Million CNY | -0.71% |
| 2023 Q2 | 205.27 Million CNY | -1.08% |
| 2022 Q3 | 478.19 Million CNY | 1.43% |
| 2022 Q2 | 471.44 Million CNY | -35.35% |
| 2022 Q1 | 729.25 Million CNY | 82.12% |
| 2022 FY | 2.45 Billion CNY | 61.98% |
| 2022 Q4 | 779.58 Million CNY | 63.03% |
| 2021 Q3 | 400.64 Million CNY | 85.48% |
| 2021 Q1 | 500.71 Million CNY | 30.71% |
| 2021 Q2 | 216 Million CNY | -56.86% |
| 2021 FY | 1.51 Billion CNY | 6.08% |
| 2021 Q4 | 400.41 Million CNY | -0.06% |
| 2020 Q1 | 195.42 Million CNY | 0.0% |
| 2020 FY | 1.43 Billion CNY | 532.28% |
| 2020 Q3 | 306.02 Million CNY | -43.98% |
| 2020 Q2 | 546.3 Million CNY | 179.54% |
| 2020 Q4 | 383.07 Million CNY | 25.18% |
| 2019 FY | 226.29 Million CNY | 60.54% |
| 2018 FY | 140.96 Million CNY | 56.63% |
| 2017 FY | 89.99 Million CNY | 0.0% |